Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (November 2005)
49 slides from Anesiva's merger presentation, Nov 4, 2005
Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation
Creating a Late-Stage Company Focused on Pain Management and Inflammation November 4, 2005
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," " forecast," "anticipate," "intend," "pl
Slide 3: Forward Looking Statements (2)
FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. has filed a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. have filed a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgen
Slide 4: AlgoRx Pharmaceuticals, Inc. / Corgentech
Algok @ Pharmaceuticals, Inc. CORGENTECH
Slide 5: Creating a Late-Stage Company
CREATING LATE-STAGE COMPANY Four product development programs focused on significant clinical problems with attractive market potential – Each drug has unique mechanism of action offering risk diversification – Each drug has potential for approval in multiple indications – Each drug can be commercia
Slide 6: Prevalence of Pain in Seven Major Countries
Above indications are all targets of Corgentech pipeline PATIENT NUMBERS PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES Prevalence of post-operative pain 75,068,000 Prevalence of back pain 208,996,000 Prevalence of HIV and AIDS pain 847,000 Prevalence of diabetic neuropathy pain 13,243,000 Prevalence o
Slide 7: Shortcomings of Current Treatments for Pain
SHORTCOMINGS OF CURRENT TREATMENTS FOR PAIN Slow onset of action Insufficient efficacy Occurrence of side effects Need for frequent dosing Lack of site specificity Potential to cause physical dependence
Slide 8: Product Pipeline
ALGRX 3268 ALGRX 4975 * ALGRX 1207 * NF-kB Decoy * PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Pre-procedural analgesia (003) Pre-procedural analgesia (004) Post-surgical pain Morton’s neuroma Tendonitis Cutaneous neuropathic pain Atopic dermatitis (eczema) * Does not reflect comprehensive
Slide 9: Combined Company: Pain Management and Inflammation
Pain Management and Inflammation COMBINED COMPANY Clear Regulatory Pathways Faster, Less Expensive Trials Substantial Body of Preclinical and Clinical Data Differentiated Products with Clear Advantages over Current Therapies Unmet or Underserved Medical Needs Sizable Patient Populations
Slide 10: AlgoRx Pharmaceuticals, Inc. / Corgentech
Algok @ Pharmaceuticals, Inc. CORGENTECH
Slide 11: ALGRX 3268: Topical Local Anesthesia
ALGRX 3268- TOPICAL LOCAL ANESTHESIA Key desirable product attributes – Sterile, pre-filled, needle-free disposable delivery system (Powderject ® ) – Rapid onset of action Within 1 minute with duration of about 10 minutes – No vasoconstriction with good dermal tolerability – Ease of use with no dres
Slide 12: ALGRX 3268 Rapid Onset of Action vs EMLA
ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a pretreatment period of at least one hour -30 -20 -10 Time after administration, minutes ALGRX 3268 Rapid Onset of Action Critical to Adoption of Product ALGRX 3268 Data from Phase 1 trial in 272 adults EMLA Package Insert for E
Slide 13: ALGRX 3268 Development
Protocol Age Group Phase Total Patients Primary Endpoint Status Antecubital Fossa Adults Safety and Efficacy Primary Endpoint Achieved Back of Hand Adults Safety and Efficacy Primary Endpoint Achieved Pharmacokinetics Adults Evaluate Circulating Lidocaine Primary Endpoint Achieved Antecubital Fossa
Slide 14: Phase 3s: Pediatric Trials
PHASE 3’s: PEDIATRIC TRIALS IDENTICAL PROTOCOLS Design – U.S. multicenter, randomized, double-blind, placebo-controlled Number of subjects – 500-600 subjects in each study Population – Pediatric subjects of either gender (ages 3-18) Objectives – Confirm efficacy, safety and tolerability of ALGRX 326
Slide 15: First Phase 3 Results
FIRST PHASE 3 RESULTS Primary endpoint achieved (p=0.007) – Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale 574 patients at six U.S. clinical trial sites – ALGRX 3268 group = 289 patients (ages 3-18) – Placebo = 2
Slide 16: Projected Timeline for ALGRX 3268
PROJECTED TIMELINE FOR ALGRX 3268 Clinical – Data from second Phase 3 trial (004) expected by year’s end Regulatory – Reviewed as a drug by the FDA Analgesics and Acute Care Division Registration – File NDA in 2006 – Product approval in 2007
Slide 17: Commercial Opportunities for ALGRX 3268
COMMERCIAL OPPORTUNITIES FOR ALGRX 3268
Slide 18: ALGRX 3268: Venipuncture Markets
PROCEDURE NUMBERS Additional Target Market Includes the 66,000 Physician’s Offices, Clinical Labs and Blood Donation Centers in the U.S. ALGRX 3268: VENIPUNCTURE MARKETS Pediatric in-hospital procedures 18,000,000 Adult in-hospital emergency room visits 89,000,000 Hemodialysis patient visits 46,800,
Slide 19: Pediatric In-Hospital Market
PEDIATRIC IN-HOSPITAL MARKET Target market – Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today Low utilization of topical local anesthetics ( 12% of pediatric procedures) due to: – slow onset of action – la
Slide 20: ALGRX 3268 Drug Class Comparison
EMLA ALGRX 3268 ALGRX 3268- DRUG CLASS COMPARISON 37% blanching, 30% erythema Minimal erythema Adverse Reactions 1-2 hours after removal 10-15 minutes Duration 60 minutes to several hours 1 minute Onset of Action Messy and requires covering Minimal Preparation Ease of Use +++ +++ Efficacy
Slide 21: ALGRX 3268: Topical Local Anesthesia Market Dynamics
Current market dynamics provide an excellent opportunity for a fast acting, easy to use topical local anesthetic product like ALGRX 3268 ALGRX 3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric h
Slide 22: ALGRX 3268: Potential Pediatric Market
POTENTIAL SALES POTENTIAL ANNUAL PROCEDURES STRAWMAN UNIT PRICE Superior Product Profile + Promotional Efforts = Market Penetration and Market Growth ALGRX 3268: POTENTIAL PEDIATRIC MARKET $60mm - $80mm 5mm $12 - $16* $72mm - $96mm 6mm $12 - $16* $48mm - $64mm 4mm $12 - $16* $36mm - $48mm 3mm $12 -
Slide 23: ALGRX 3268: Phased Marketing Approach
ALGRX 3268: PHASED MARKETING APPROACH In-hospital Pediatric 18M
Slide 24: AlgoRx Pharmaceuticals, Inc. / Corgentech
Algok @ Pharmaceuticals, Inc. CORGENTECH
Slide 25: ALGRX 4975 – VR1 Anesthetic: Capsaicin Overview
Capsaicin Overview Blocks noxious pain with long duration ALGRX 4975 – VR1 ANESTHETIC Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fi
Slide 26: ALGRX 4975: Proof of Concept Established
TARGET MARKETS MODEL FOR STUDY ALGRX 4975: PROOF OF CONCEPT ESTABLISHED Delay progression to surgery Musculoskeletal Pain Tendonitis / Osteoarthritis Complex Regional Pain Syndrome (CRPS) Local Neuropathic Pain Morton’s Neuroma Joint Replacement Post-Surgical Pain Bunionectomy
Slide 27: ALGRX 4975 Development
ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery Time to Rescue Medication 72-hour Endpoint Achieved Bunion Removal Surgery Magnitude of Pain Relief 24 and 72- hour Endpoints Achieved Hernia Repair Magnitude and Duration of Pain Re
Slide 28: Morton's Neuroma
MORTON’S NEUROMA Type of localized post- trauma neuropathic pain Painful foot condition that typically occurs as a result of: – Running – Wearing high narrow shoes – Excessive standing Neuroma (thickened nerve tissue) – Forms as a result of injury to one of the nerves that leads to the toes – Leads
Slide 29: Phase 2 Results: Morton's Neuroma
PHASE 2 RESULTS: MORTON’S NEUROMA Objectives – Confirm efficacy, safety and tolerability of ALGRX 4975 vs. placebo administered by single injection into neuroma Design and population – U.S. randomized, double-blind, placebo-controlled – 58 subjects of either gender at two U.S. clinical trial sites A
Slide 30: Commercial Opportunities for ALGRX 4975
COMMERCIAL OPPORTUNITIES FOR ALGRX 4975
Slide 31: ALGRX 4975: U.S. Post-Surgical and Neuropathic Pain Markets
PROCEDURE NUMBERS ALGRX 4975: U.S. POST-SURGICAL AND NEUROPATHIC PAIN MARKETS POST-SURGICAL PAIN Bunionectomy 709,000 Cholecystectomy 1,230,000 Total knee replacement 412,000 Total hip replacement 346,000 Hernia repair 825,000 Hysterectomy 789,090 LOCAL NEUROPATHIC PAIN 1,269,000 TOTAL 5,580,090
Slide 32: Post-Op Pain Drug Comparison
Opioids ALGRX 4975 POST-OP PAIN DRUG COMPARISON Hours Weeks Duration Rapid Rapid Onset of action Respiratory depression, nausea, vomiting, ileus Cannot inject near large nerves Safety Frequent Single application Dosing +++ +++ Efficacy
Slide 33: ALGRX 4975: Post-Operative Pain Market
ALGRX 4975: POST-OPERATIVE PAIN MARKET U.S. post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively Pain in hospital associated with increased length of stay, longer recovery times, poorer patient outcomes
Slide 34: Post-Trauma Neuropathic Pain: Background
POST-TRAUMA NEUROPATHIC PAIN: BACKGROUND Approximately 1.2 million Americans suffer from a localized form of neuropathic pain resulting from trauma or surgery – Pain lasting months and often severe and debilitating Occurs following 10% of general and 30% of orthopedic surgeries – Most commonly assoc
Slide 35: ALGRX 4975: Neuropathic Pain Market
ALGRX 4975: NEUROPATHIC PAIN MARKET No drugs indicated for Morton’s neuroma or other post trauma neuropathic pain syndromes – Off label usage of Neurontin, Lidoderms, antidepressants and opioids U.S. neuropathic pain market: $1.9 billion Despite employing concomitant treatment with several drugs wit
Slide 36: ALGRX 4975: Blockbuster Potential
ALGRX 4975: BLOCKBUSTER POTENTIAL Significant unmet medical need Attractive product profile Large surgical volume Small target audience Specialized sales forces
Slide 37: Avrina (NF-kB Decoy) for Eczema
AVRINA™ (NF- k B DECOY) FOR ECZEMA
Slide 38: Common, Chronic Problem
COMMON, CHRONIC PROBLEM Eczema (Atopic Dermatitis) – Red, cracked, and unbearably itchy skin caused by excess inflammation in the skin – Makes the person more susceptible to infection 90% of people with AD have staph bacteria on their skin compared to <5% of people without AD – Affects about 15 mill
Slide 39: Attractive Indication
ATTRACTIVE INDICATION Unmet medical need – Existing therapies are not satisfactory (steroid and calcineurin inhibitors) – Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on on calcineurin inhibitors Strong preclinical data showing e
Slide 40: Lack of Rebound with NF-kB Decoy
Stop Treatment LACK OF REBOUND WITH NF- B DECOY Start Daily Treatment Placebo NF- B Decoy Betamethasone Days
Slide 41: Drug Comparison
Steroids Calcineurin Inhibitors NF- B Decoy DRUG COMPARISON None Limits use None Skin-thinning ++ +++ +++ Onset of action Black box warning for cancer risk May cause significant side effects Limited Systemic exposure Frequent Once/twice a day Short-term +++ Occasional None Rebound Twice a day Short-
Slide 42: Commercial Opportunity
Total Dollars COMMERCIAL OPPORTUNITY $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 Corticosteroids Protopic Elidel Focused Prescriber Base •10-20% of all dermatological visits •70% of all pediatric visits to a dermatologist Growing Market with new, premium priced drugs Family Practice 9% Internal
Slide 43: AlgoRx Pharmaceuticals, Inc. / Corgentech
Algok @ Pharmaceuticals, Inc. CORGENTECH
Slide 44: ALGRX 1207
ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: – Neuropathic pain – Dermatological surgery – Surgical incisions
Slide 45: oS SS : ae : o . a Le i . : a e|seyysoue
oS SS : ae : o . a Le i . : a e|seyysoue aje|dwioo jueoleq
Slide 46: ALGRX 1207: Target Market
Drug 2004 US Sales ($ in MM) Patient Cost/ Year OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309 $1,450 Drug 2004 US Sales ($ in MM) Patient Cost/ Year ALGRX 1207:TARGET MARKET OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309
Slide 47: AlgoRx Pharmaceuticals, Inc. / Corgentech
Algok @ Pharmaceuticals, Inc. CORGENTECH
Slide 48: Delivering on Our Promises
DELIVERING ON OUR PROMISES File IND for Phase 1 Trial of ALGRX 1207 for Pain Relief Report Clinical Data from Phase 1/2 Trial of Avrina™ (NF-kB Decoy) for Eczema Report Clinical Data from Second Phase 3 Trial of ALGRX 3268 Report Clinical Data from Phase 2 Trial of ALGRX 4975 for Morton’s Neuroma Re
Slide 49: Thank You
Thank you for joining us for today’s presentation. For additional information about the proposed merger of Corgentech and AlgoRx, please visit www.corgentech.com and the other sources described in our forward looking statement slide.
Algorx Pharmaceuticals — Merger or Acquisition (November 2005) on 6ix